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Rift Valley fever virus (RVFV) is a mosquito-borne, zoonotic Phlebovirus that is a 
significant threat to ruminants and humans. RVFV is categorized as an overlap Select Agent by 
the Department of Health and Human Services and US Department of Agriculture. Therefore, 
the study of RVFV’s pathogenesis and the development of novel diagnostic tools for the 
prevention and control of outbreaks and virus spread is crucial. RVF is endemic to sub-Saharan 
Africa but has spread beyond the continent to the Arabian Peninsula indicating the competence 
of the virus to emerge in new areas. Thus, the high likelihood of RVF’s spread to other non-
endemic countries also spurs the need for development and implementation of rapid diagnostic 
tests and surveillance programs. In the US, RVFV is a Select Agent, requiring BSL-3 enhanced 
containment practices for research work. First, we developed a method for the detection of 
RVFV RNA by reverse transcriptase real-time PCR (RT-qPCR) using non-infectious, formalin-
fixed, paraffin-embedded tissues (FFPET).  The results from FFPET RT-qPCR were compared 
to prior results for fresh-frozen tissues (FFT) RT-qPCR, as well as immunohistochemistry and 
histopathology completed on the same FFPET blocks. We developed a novel technique using a 
rapid and low cost magnetic bead extraction method for recovery of amplifiable RVFV RNA 
from FFPET. FFPET RT-qPCR can serve as an alternative tissue-based diagnostic test, which 
does not require a BSL-3 research facility. Second, we assessed the diagnostic accuracy and 
precision of a recombinant RVFV nucleoprotein based competitive ELISA (cELISA) assay to 
detect RVFV antibodies. The cELISA results were compared to the virus neutralization test, the 
gold standard serological assay for RVFV. This prototype cELISA is an easy to implement, 
sensitive, specific, and safe test for the detection of antibodies to RVFV in diagnostic and 
surveillance applications. RVF is an important transboundary disease that should be monitored 
  
on a regular basis. The diagnostic tests developed and validated in this thesis could be used in 
endemic or non-endemic countries for the early detection of RVF and assist with the 
implementation of countermeasures against RVFV. 
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Chapter 1 - Literature Review 
Introduction  
Rift Valley fever virus (RVFV) is a mosquito-borne, zoonotic pathogen of serious 
concern to animal and public health. RVFV is an important transboundary pathogen due to the 
significant potential for its international spread and use as a biological weapon1. It is categorized 
as a Select Agent by the Centers for Disease Control and Prevention (CDC) and the United 
States Department of Agriculture (USDA)2. Rift Valley Fever (RVF) is an emerging infectious 
disease with no therapeutic measures1 and no fully licensed vaccine for humans. The presence of 
a wide range of competent mosquito vectors3, global climate change, and international travel and 
trade4 have highlighted RVF as a significant threat to both animal and public health. Therefore, 
study of its pathogenesis, development of effective and efficient diagnostic tools, and RVF 
prevention are very crucial5. Additionally, the increasing number of human deaths and the 
possibility of its transmission internationally have emphasized the need for development of 
therapeutics and countermeasures for the control of the disease. After the optimization and 
development of diagnostic tests, it important to conduct a thorough validation that provides 
evidence of fitness to purpose of the assay along with quality assessment6.  
RVFV virion 
RVFV belongs to an order Bunyavirales, family Phenuiviridae and genus Phlebovirus. 
The RVFV virion (Fig.1.1) is spherical with an icosahedral symmetry and measures 90-110 nm 
in diameter. The virus’ envelope is composed of a lipid bilayer studded with 12 nm long 
glycoproteins (Gn and Gc)7. RVFV is a tri-segmented, single-stranded, primarily negative-sense 
RNA virus. The three gene (tripartite) segments are designated as large (L; 6404 nucleotides), 
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medium (M; 3885 nucleotides), and small (S; 1690 nucleotides). The L and M segments are 
negative sense while the S segment is ambisense.  
The L segment encodes the RNA-dependent RNA polymerase (RdRp). The RdRp (259 
kDa), which is the largest protein, plays a major role in replication and mRNA synthesis8,9. Like 
influenza virus, RVFV uses a ‘cap-snatching’ mechanism for mRNA synthesis. For the priming 
of mRNA synthesis during the transcription process, the viral endonuclease activity of the RdRp 
cleaves the short fragments of 5’caps from host mRNA9,10. This process occurs in the 
cytoplasm11.  
The M segment encodes the major envelope glycoproteins, Gn and Gc, and two 
nonstructural proteins NSm (78kDa and 14kDa). A single mRNA transcribed from the M 
segment of RVFV translates into a polyprotein. Then the polyprotein is processed by cellular 
enzymes to form Gn (approximately 54 kDa) and Gc (approximately 59 kDa)12, and at least two 
additional non-structural proteins, NSm (78kDa and 14kDa)13,14. While Gn and Gc play a crucial 
role in viral replication and pathogenesis, the function of NSm is not well understood15. Some 
studies have shown that NSm is not essential for either virulence12 or viral replication in cell 
cultures15. In contrast, another study revealed that the NSm suppresses apoptosis thus, has a role 
in viral pathogenicity16. During infection, Gn and Gc play a role in viral binding and entry17,18. 
Also, they induce the production of neutralizing antibodies and elicit the protective humoral 
immune response19. Thus, these glycoproteins can be valuable targets for the development of 
serological tests and vaccines for RVFV.  
The S segment encodes the nucleocapsid protein, Np, and a non-structural protein, NSs20. 
The Np is highly immunogenic and abundantly present in the virus. However, it only induces 
partially protective immunity because it cannot elicit neutralizing antibodies5. While Np is less 
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likely directly involved in pathogenesis, the NSs protein plays a critical role in RVFV 
pathogenesis and replication. The NSs protein is the major virulence factor of RVFV. It has 
antagonistic activity against interferons21. Also, the NSs protein induces the degradation of 
dsRNA-dependent protein kinase, which suppresses viral translation22. Though RVFV replicates 
in the cytoplasm, it forms filamentous structures in the nuclei of infected cells that interact with 
several cellular nuclear proteins, thus obstructing the cellular antiviral response23. 
The Np along with the RNA genome and viral RdRp form the ribonucleoprotein 
complexes (RNP)24. Since RVFV does not have a matrix protein, direct interaction between the 
glycoproteins and the RNP takes place25. 
 
Figure 1.1 Structure of RVFV virion 
Life cycle of the RVFV 
The dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-
SIGN), which is expressed on the surface of dendritic cells has been identified as a receptor for 
RVFV26. Since RVFV has broad cell tropism, the glycosaminoglycan heparan sulfate, a 
polysaccharide found in animal cells may also facilitate the attachment and entry of RVFV in the 
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absence of DC-SIGN expression27. After attachment, the virus enters into the cell through 
caveolar-mediated endocytosis28. The class II fusion glycoprotein Gc, which is activated at low 
pH after endocytosis enables the fusion of the virion and cell membranes29,30. This allows the 
release of RNP into the cytoplasm where transcription and replication of all 3 gene segments 
occurs.   
The RdRp plays a role in replication of each gene segment, which results in the 
generation of complementary RNA (cRNA). An important characteristic of the ambisense RVFV 
S segment RNA is that the genomic RNA also acts as cRNA. The cRNA functions as the 
template for the synthesis of NSs mRNA. As a result, early translation of NSs occurs and the 
protein plays a role in suppressing the host’s innate immunity31. 
Assembly and maturation begins with the localization of Gn and Gc in the Golgi 
apparatus through the translocation signal peptide present on Gn32–34. After the recruitment of 
other structural proteins and the gene segments in the Golgi, mature virions form by viral 
budding. Then the Golgi complex undergoes morphological changes that result in many small 
and large vacuoles. These vacuoles help in the transport of mature virions to the cell’s surface 
where they fuse to the plasma membrane and are released from the cell20. 
Rift Valley fever disease 
In 2015, the WHO listed Rift Valley fever (RVF) among the top emerging diseases likely 
to cause major epidemics and in need of critical attention35. RVFV is a mosquito-borne 
Phlebovirus that infects a broad range of hosts including sheep, cattle, goats, buffalo, camels, 
and humans. The susceptibility of RVFV infection depends on livestock species, age, and viral 
strain36. The major target organs include liver, spleen and brain37. The clinical manifestation of 
RVF disease in ruminants ranges from mild, asymptomatic, self-limited illness to severe disease 
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including hemorrhagic fever, retinal vasculitis, hepatitis, and encephalitis38–41. Milder symptoms 
include injected conjunctiva, nasal discharge, weakness, and decreased milk production42. While 
most of the RVF cases in humans are asymptomatic and mild, a small proportion of patients have 
severe complications43. 
Transmission 
RVFV is transmitted to livestock by mosquitoes and transmission between animals also 
occurs44. Humans acquire RVFV through numerous routes: direct contact with infected animal 
tissues, blood, or other body fluids; inhalation of aerosolized infected fluids; and transmission 
through bites of infected mosquito vectors45,46. More than 30 species of mosquitoes are 
responsible for the transmission of RVFV, however, Aedes spp. and Culex spp. are considered to 
be the main vectors47,48. The transmission cycle of RVFV involves an enzootic and an 
epizootic/epidemic cycle49. During non-excessive rainfall, the transovarian transmission of the 
virus to the next generation of mosquitoes plays a crucial role in order to maintain the enzootic 
cycle. This enzootic cycle is primarily maintained by Aedes spp.50,51. The conversion of the 
enzootic cycle into an epizootic cycle occurs with heavy and prolonged rainfall after which the 
eggs started to hatch48,50. Culex spp. are the amplifying vectors that play role in the epizootic 
cycle50,52.  
The risk of RVFV introduction into non-endemic regions is of great concern. The 
potential routes of transmission to non-endemic countries are through the movement of infected 
travelers and mosquitoes as well as international trade of infected animals53. Moreover, the 
presence of numerous competent vectors of RVFV in non-endemic regions increases the risk. 
Thus, surveillance of livestock that are imported into non-endemic regions as well as those 
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already present within endemic regions using validated tests is critical. Additionally, vector 
control programs could reduce the risk of introduction of RVFV54.  
Epidemiology 
RVFV has been reported in Africa and the Arabian Peninsula. Sudden abortions in 
livestock following heavy rainfall are indicative of a possible RVF outbreak46. RVFV was first 
described in 1930 during an outbreak of enzootic hepatitis in a herd of ewes in the Great Rift 
Valley of Kenya55. Two large epizootics occurred during 1950-195156 and 1974-197657. Also, 
there have been several sporadic outbreaks since 1950 in South Africa. A major RVFV outbreak 
was documented in Egypt in 1977 with 20,000–200,000 human clinical illnesses and 600 
deaths58–60 and another in Mauritania in the late 1980s61.  The emergence of mosquito vectors 
due to Nile river flooding and animal trade were the suspected reasons for the outbreak in 
Egypt62. Fifteen years later in 1993, Egypt experienced a second outbreak. A key factor in this 
second outbreak was continuous movements of livestock42. Subsequently, in 2000, RVFV spread 
beyond Africa to Saudi Arabia and Yemen60. It was estimated that 40,000 animals died or were 
aborted and there were also 124 human deaths in Saudi Arabia54. RVFV epidemics were 
documented in several countries during 2006-2008: Somalia, Kenya, Tanzania, Sudan, Mayotte, 
and Madagascar63. In particular, the 2006 and 2007 epidemics in eastern Africa had a devastating 
effect in Kenya, Tanzania, and Somalia with significant livestock losses and 698 human 
deaths64,65. 
Several RVFV outbreak studies have been conducted. They have focused on the pattern 
of the outbreaks, including their association with environmental, geographical and geological 
factors as well as the risk factors associated with infection66–68. Hightower et al., 2012 concluded 
that the areas with heavy rainfall and flooding, poor drainage, flat landforms, and presence of 
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competent vectors have a high risk of occurrence of RVFV69. Humans who are in direct contact 
with infected animals are also at a high risk45. Therefore, continuous monitoring of competent 
vectors, surveillance for virus in animals, and risk analysis of the introduction of the virus into 
non-endemic regions are necessary. 
Diagnosis of RVF 
RVFV research is limited because it must be conducted in high containment 
laboratories70. Consequently, the development of safe, effective, and efficient diagnostic 
measures is both a challenge and an opportunity. RVFV is a hemorrhagic fever virus and listed 
as a category ‘A’ bioterrorism agent by the Centers for Disease Control and Prevention (CDC)71. 
Thus, RVFV poses a significant threat as a biological weapon, further emphasizing the need for 
rapid diagnosis. Several assays including the detection of the whole virus, antibodies, antigens, 
and nucleic acids have been developed for RVFV. Virus isolation, polymerase chain reaction 
(PCR), immunohistochemistry, and serological tests are the diagnostic techniques available for 
RVFV. According to the World Organization for Animal Health (OIE), a combination of at least 
two positive results from two different diagnostic tests is required for the confirmation of RVFV 
in animals72. Also, in endemic areas, a combination of clinical signs and symptoms with 
diagnostic tests are used for the confirmation of RVFV63.  
Virus isolation 
Virus isolation can be performed using serum, plasma or whole blood collected during 
the febrile period (3-4 days)73 of the disease in animals. Also, the virus can be isolated from 
different animal tissues (liver, spleen, and brain) at necropsy as well as aborted fetuses. Both in 
vitro and in vivo virus isolation can be performed. Since in vivo virus isolation requires 
intracerebral inoculation of suckling mice/hamsters, the OIE recommends in vitro methods using 
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cell lines due to animal welfare and biosafety concerns72. Various cell lines including African 
green monkey kidney cells, baby hamster kidney cells, and AP61 mosquito cells are used for in 
vitro isolation of RVFV. Consistent cytopathic effect of RVFV can be observed within 12–24 h 
post-infection in mammalian cell lines74. The combination of virus isolation with 
immunohistochemistry or reverse-transcription polymerase chain reaction (RT-PCR) is 
necessary for confirmation72. Virus isolation is costly, laborious, and requires biocontainment 
facilities for the propagation of live virus75,76. Thus, there is need for the development of 
diagnostic tools that are rapid and minimize the handling of live virus.  
Viral antigen detection by immunohistochemistry 
Immunohistochemistry (IHC), performed on formalin-fixed, paraffin-embedded tissues 
(FFPET), is a sensitive and specific technique for the detection of viral antigens in tissues, 
enabling visualization of RVFV antigen with histopathological context. Since 10 percent neutral 
buffered formalin, the standard tissue preservative, inactivates the virus, IHC can be conducted 
in a BSL-2 laboratory77. Currently, IHC in combination with histopathology is the confirmatory 
diagnostic tool of choice for the detection of RVFV in tissues77,78. In addition to its diagnostic 
use, IHC is used for retrospective studies.  
 The selection of tissue/organ sample is crucial for successful IHC79. Although liver and 
spleen are the preferred organs78,80,81 for RVFV diagnosis, kidney, lymph node and lungs are also 
valuable samples for the detection of RVFV antigen36,82–84. Validated antibodies must be used to 
ensure the sensitivity and specificity of IHC. Additionally, IHC results are influenced by the 
quality of tissue samples79. Factors such as tissue collection, handling, preservation, and 
transportation to the laboratory need to be considered for successful IHC. Since, standardization 
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of sample collection, transport and IHC protocol are all needed for reliable IHC results, RVFV 
IHC should only be conducted in established laboratories.  
Viral antigen/antibody detection by serological methods 
Serological methods, either detection of antigen or antibody, are used both for 
surveillance of susceptible populations and outbreak management. Classical serological tests for 
RVFV are agar gel immunodiffusion, radioimmunoassay, hemagglutinin inhibition, and 
complement fixation72. Currently, the virus neutralization test (VNT) and enzyme-linked 
immunosorbent assay (ELISA) are more commonly used85. 
The VNT is considered the gold standard serological test86. When a comparison was 
made between different serological diagnostic tests for the detection of antibodies against RVFV, 
the VNT was discovered to have the highest sensitivity and specificity87. But the VNT is a 
costly, laborious, and time-consuming procedure with potential health risks for laboratory 
personnel performing the assay in biocontainment88,89. Therefore, ELISA offers an alternative for 
the detection of antibodies or antigens against RVFV.  
The ELISA is a safe, rapid, sensitive, and specific test, which is used to test animals 
during import and export, surveillance and control programs. Also, monitoring of the immune 
system of animals during vaccination can be conducted using ELISA tests90,91. The ELISA is 
widely used for the detection of RVFV-specific IgM or IgG in animal or human sera. Anti-
RVFV IgM antibodies can be detected from 4 days after infection and are transient. For example, 
Paweska et al., 2005 showed that an IgM-capture ELISA can detect RVFV antibodies within 6-
22 days after onset of symptoms in naturally infected humans89. The detection of anti-RVFV 
IgM antibodies implies a recent infection. Anti-RVFV IgG antibodies can be detected from 8 
days after infection and may persist for several years. Consequently, paired serum samples are 
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needed in order to differentiate between past and current infection74,91–93. There are several 
ELISA formats that use cell lysate or purified protein as the target antigen for the detection of 
antibodies against RVFV89,91,94,95. Also, ELISAs based on recombinant nucleoprotein (recNp), 
which does not require a biocontainment facility for their production or use, have been 
reported75,88. 
Detection of RVFV antigen using ELISA could be an alternative for detection of 
antibodies against RVFV because the antibodies against the virus may not be detectable during 
the first few days of infection96,97. However, the assays for detection of viral antigen lack 
sensitivity92 and require reagents that are costly and challenging to produce75. Due to these 
limitations of antigen detection ELISAs, IgM or IgG ELISAs for the detection of antibodies 
against RVFV are widely used92.  
With the limitations of classical serological methods, the ELISA technique is in wide use 
for the detection of antibodies. However, lack of international standardization, lack of inter-assay 
consistency, and full validation of ELISA techniques have been challenges to the use of 
ELISA98.  Although ELISA is more sensitive than classical methods for the diagnosis of RVFV, 
non-specific binding and cross-reactivity with other Phleboviruses is a major concern91. Thus, 
complete validation of each ELISA test is crucial before using it as a diagnostic or surveillance 
test.   
Nucleic acid detection by PCR 
Some molecular methods, specifically the detection of viral RNA, are rapid and 
economic techniques for the detection of RVFV genome, and therefore are an excellent 
alternative to virus isolation and serological methods. They are valuable for effective 
management of outbreaks because they can detect the presence of viral RNA rapidly enabling 
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swift application of appropriate control measures99. Various rapid and accurate molecular 
methods have been developed and additional studies are underway for the development and 
evaluation of molecular diagnostic tests.  
Several reverse transcriptase polymerase chain reaction (RT-PCR) and real time RT-PCR 
(RT-qPCR) methods have been developed100–104. These methods have a limit of detection 
between 10 and 100 genome copies105 and are recommended by OIE72. While expensive 
equipment is required to conduct RT-qPCR, it is the most commonly used technique for the 
detection and quantification of RVFV RNA due to its high analytical sensitivity and 
specificity106. Also, when compared with conventional RT-PCR, RT-qPCR is a rapid, 
standardized, quantitative method with less chance of contamination. 
Reverse transcription loop-mediated isothermal amplification (RT-LAMP) and 
recombinase polymerase reaction (RPA) are simple and sensitive techniques. These techniques 
use an isothermal reaction, which is feasible for rapid detection in the field. Since an outbreak of 
RVFV can occur in remote areas and can become catastrophic within a short time period, the 
development and evaluation of field deployable molecular techniques would be useful to 
diagnose and employ control measures effectively63. Although six sets of primers are needed for 
RT-LAMP, it is a single step, rapid, simple, and cost-effective assay for the amplification of L 
segment of RVFV107,108. Moreover, RT-LAMP is a sensitive and specific assay comparable to 
RT-qPCR105. Similarly, RPA is also a rapid and sensitive assay that uses primers and probes 
similar to those used for RT-qPCR in contrast to complex primers used for RT-LAMP. However, 
RPA requires a portable fluorescence reader for field use109. 
Ebola, Marburg, Lassa, Dengue, and Yellow fever viruses like RVFV are the important 
causative agents of viral hemorrhagic fevers (VHFs). Considering that VHFs have common signs 
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and symptoms and are clinically challenging to differentiate, multiplex RT-PCR assays have 
been developed for simultaneous detection of multiple pathogens110,71. These assays are 
important for accurate and rapid diagnosis needed to control spread and apply appropriate 
treatment, particularly in areas where multiple VHF pathogens are endemic111. 
Molecular methods are sensitive but variation in results can occur in different laboratory 
settings. Thus, a standardized protocol and controls are required when performing the test to 
reduce this variation as well as detect contamination issues99. During RVF outbreaks, molecular 
methods are particularly beneficial for the detection of RVFV RNA at early infection time-points 
when antibodies cannot be detected101. Therefore, molecular methods are useful for early 
diagnosis in order to control and prevent the spread of RVF disease. However, the need for 
specialized instrumentation and skilled laboratory personnel as well as the short time period of 
viremia pose challenges for the use of molecular methods for the detection of RVFV RNA, 
especially for outbreaks in remote regions75. 
Diagnostic Assay Validation 
Validation of an assay is a series of inter-related processes that are conducted to 
determine the competence of well-developed and optimized assay for an intended purpose112. It 
is critical for any developed assay to have a complete validation before its commercial use.  A 
fully validated assay has the capability of identifying an analyte present in the given sample and 
classifying the animal as positive or negative113. Several factors need to be optimized and tested 
during the assay development and validation pathways. According to OIE6, after the 
development and optimization of an assay, the validation pathways comprise of four stages; 
Stage 1: analytical characteristics; Stage 2: diagnostic characteristics; Stage 3: reproducibility; 
Stage 4: implementation. Along with the development and validation pathways, monitoring of 
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the assay performance after initial validation is critical, requiring continuous monitoring, 
evaluation, and maintenance of the assay. 
RVFV vaccines  
It has been more than eight decades since the discovery of RVFV82, but the development 
of a safe and efficient vaccine for human and animals is still a challenge114. Moreover, there are 
no specific therapeutic measures available for RVF74. A vaccine is a modified form of a natural 
immunogen. It may be either the whole pathogen, one of its components, or a toxin.  Ideally, it 
should be easy to administer, single dose, provide long-term immunity, unable to revert to 
virulent virus, stable at room temperature, and cost-effective. Additionally, vaccines that allow 
the differentiating of infected animals from vaccinated (DIVA) are important for international 
trade and surveillance115. Strategies tried for RVFV vaccines include live virus attenuation, virus 
inactivation, virus-like particles, recombinant viral vectors and DNA vaccines5. Three licensed 
veterinary RVF vaccines (Smithburn vaccine, a formalin-inactivated vaccine derived from 
Entebbe strain, and Clone 13) are available for use in endemic regions. In the US, live-attenuated 
mutagenized passage-12 (MP-12) vaccine strain is conditionally licensed for animal 
vaccination116. 
The Smithburn strain, a live attenuated vaccine developed in 1940, was the first RVF 
vaccine117. Although Smithburn strain is still being used, it is not safe for young animals or 
gestating adults. Moreover, the risk of reversion of this vaccine strain to full virulence drove the 
need for alternative vaccines118,119. Consequently, two other live attenuated vaccines, MP-12 and 
Clone 13 were developed.  
Clone 13 is a naturally attenuated RVFV isolate with a large deletion in the NSs gene120. 
When this vaccine was first evaluated in sheep, effective protection with no pathogenic side 
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effects and no abortions in pregnant ewes was observed121. In contrast, a recent study concluded 
that Clone 13 can cross the sheep placental barrier causing fetal infections, malformations, and 
stillbirths122.  
MP-12 was produced by serial passaging of the Zagazig Hospital 548 (ZH548) RVFV 
strain 12 times in the presence of mutagen 5-fluorouracil. The vaccine is considered to be 
effective in sheep and cattle5. A human phase II clinical trial was conducted for MP-12 vaccine 
in which no reversions of vaccine virus (in attenuated regions) to wild-type RVFV occurred as 
confirmed by genetic analysis123. However, the mechanisms of MP-12 attenuation are still not 
fully understood114,124. Also, in a study in pregnant ewes, MP-12 caused teratogenic effect, 
malformations, and abortion in sheep125 and in another experimental study, 6 out of 10 four-
month old calves inoculated with MP-12 had multifocal, hepatic necrosis and one calf’s liver 
was positive for RVFV antigen by IHC126.  
Finally, no licensed vaccine for humans is available, in the US, RVFV TSI-GSD-200 is 
used for military and at-risk laboratory personnel and is provided by the U.S. Army Medical 
Research Institute of Infectious Diseases (USAMRIID). Unfortunately, it is an inactivated 
vaccine that requires multiple inoculations and enrollment in a costly clinical trial program127. 
Since humans typically get infected after contact with infected animals, effective vaccination of 
ruminants can also help prevent RVF in humans. Overall, there is significant room for 
improvement in licensed vaccine options and therapeutics for RVF. 
FFPET as a diagnostic specimen 
FFPET has been extensively used for histopathology and IHC for the diagnosis of many 
infectious diseases. FFPET archives serve as an invaluable source of information for molecular 
genetics research128,129. Recent studies have also revealed that FFPET could be a potential source 
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of material for retrospective analysis using RT-qPCR and microarrays techniques130,131. When 
compared with fresh frozen tissue as a specimen for analysis, FFPET is cheaper to store for a 
long period of time, stable at room temperature, and easier to process. Moreover, the 
retrospective investigation of etiology and epidemiology of disease can be conducted using 
FFPET131,132.  
Unfortunately, nucleic acid obtained from FFPET is of low quality and it is harder to 
extract amplifiable RNA/DNA from FFPET in comparison to fresh-frozen tissues132–135. The 
preservation process for FFPET specimens involves 10% neutral buffered formalin fixation, for 
at least 24 h, typically followed by a 12 h long procedure in an automatic processor using 
formalin, various graded alcohols, xylenes, and paraffin infiltration then finally, embedding in 
paraffin. These aforementioned processes induce fragmentation of the nucleic acids and formalin 
specifically induces chemical modification of the RNA/DNA by addition of monomethylol (-
CH2OH) group to the nucleotides of RNA as well as cross-linking of nucleic acids (NA) with 
proteins136–140. The methylol addition inhibits the reverse transcription process decreasing the 
sensitivity of RT-PCR136. The crosslinking between NA and proteins causes restrictions during 
the extension of the primer137. Thus, the attainment of sufficient and stable RNA from FFPET is 
challenging. In spite of the technical challenges, FFPET is used as a specimen to study tumor 
gene expression128,129,141 as well as for the detection of viral RNA142–144.  
Although several studies have been conducted using FFPET, there is no standard protocol 
for the deparaffinization and extraction of nucleic acids145,146. There are many factors that affect 
FFPET PCR results including the age of FFPET blocks, degree of tissue autolysis prior to 
preservation, fixative quality, fixation time, tissue type, and nucleic acid extraction procedure147–
149. Thus, standardization and optimization of protocols are necessary before it will be possible to 
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obtain the same quality and quantity of nucleic acids from FFPET in different laboratory 
settings. 
Gaps in Knowledge 
Definitive diagnosis is critical for RVF and there are only a few validated assays 
available. FFPET has been used for detection of RVFV using histopathology in combination 
with IHC technique, however, to our knowledge it has not been successfully used for further 
molecular analysis. A study was conducted to purify suitable RVFV RNA from archived FFPET 
for gel-based reverse transcriptase PCR (RT-PCR) and next generation sequencing but no RT-
PCR amplicons were achieved150. A reliable method for the quantitative detection of viral RNA 
from RVFV infected FFPET does not exist.  
Serological tests have always been one of the easiest methods for the diagnosis of 
infectious disease. ELISA tests using recNp offer a safe, reliable, effective, and efficient 
alternative technique. They do not require handling of live virus and their production and use can 
be conducted outside of biocontainment facilities151. While a prototype recNp cELISA had been 
developed for the USDA Animal and Plant Health Inspection Service (APHIS) National 
Veterinary Stockpile, it was not yet validated.   
Purpose of research  
We addressed the aforementioned gaps in RVFV diagnostics. First, we developed and 
validated a protocol for sensitive and specific extraction of RVFV RNA from FFPET. The 
protocol uses a rapid, low cost magnetic bead nucleic acid extraction enables sensitive detection 
of RNA specific for RVFV and for PCR we used the Wilson et al., 2013 RVFV multiplex 
PCR152. Next, we determined the diagnostic accuracy and precision of the aforementioned RVFV 
recNp cELISA. Both of these techniques are at OIE stage 2 of validation and required the 
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inclusion of field samples from endemic countries to move to stage 3. With further validation, 
these tests should contribute to the detection of RVFV and help in prevention and control of 
RVFV during outbreaks. Additionally, the RT-qPCR technique using FFPET should be suitable 
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Rift Valley fever virus (RVFV), a mosquito-borne zoonotic pathogen (genus 
Phlebovirus; family Phenuiviridae; order: Bunyavirales)153, is endemic to sub-Saharan African 
countries73. It is an enveloped, single-stranded, ambisense polarity RNA virus with three gene 
segments designated as L (large; 6404 nucleotides), M (medium; 3885 nucleotides), and S 
(small; 1690 nucleotides)154. RVFV is the causative agent of Rift Valley fever (RVF), a disease, 
which has devastating effects on both livestock and human health. It causes abortions and death 
in ruminants and illnesses ranging from fever, encephalitis to death in humans155.  
Since RVFV’s first isolation in Kenya in 193055, there have been many outbreaks 
reported in several countries including Kenya, Tanzania, Somalia, South Africa, Madagascar, 
Egypt, Sudan, Mauritania, Senegal, Saudi Arabia, and Yemen59. The increasing number of 
human deaths in more recent outbreaks, lack of licensed vaccines, the possibility of its spread to 
non-endemic countries, and the classification of RVFV as a Select Agent in the United States all 
emphasize the need for further study of RVFV’s pathogenesis and the development of diagnostic 
tools and medical countermeasures for RVF5,156. However, research on RVFV is limited because 
it requires BSL-3 research facilities, in particular, BSL-3Ag for research with ruminants70. To 
overcome this issue, the potential use of formalin-fixed, paraffin-embedded tissues (FFPET) for 
the detection of RVFV RNA using reverse transcription polymerase chain reaction (RT-PCR) for 
diagnostics and for conducting retrospective research is promising77. The use of FFPET for 
immunohistochemistry (IHC) in combination with histopathology is the accepted tissue-based 
confirmatory test of choice for RVFV during epidemics77. While fresh and frozen tissues (FFT) 
remain the ideal source for molecular diagnosis, FFPET is an attractive alternative research 
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material because it is safer to process and cheaper to store for a long period of time131. Moreover, 
FFPET is a better choice in the absence of a cold chain.  
Attaining sufficient and stable RNA from formalin-fixed tissues is challenging because 
formalin degrades and chemically modifies the RNA by addition of monomethylol (-CH2OH) 
group to RNA followed by cross-linking of nucleic acids (NA) with proteins136,145,157. 
Consequently, quality and quantity of nucleic acid (NA) obtained from FFPET will be low in 
comparison to FFT. Despite these limitations, FFPET is used for gene expression analysis to 
study changes during tumor progression128,129,141. FFPET has been used for the detection of 
infectious diseases including West Nile virus, enterovirus, and hepatitis C virus by RT-PCR142–
144 and high-throughput RNA sequencing of archival autopsy lung samples from 1918 pandemic 
influenza victims158. Several studies have shown that detectable RNA can be extracted 
successfully by introducing various modifications to the extraction process. By increasing the 
deparaffinization temperature, proteinase K concentration and incubation time, RNA was 
recovered from FFPET infected with BSL-3 and -4 pathogens using a Paraffin Block RNA 
isolation kit (Ambion, Texas, USA)145. Another successful study used the Optimum RNA 
isolation kit (Ambion) with modifications for the extraction of RNA from formalin-fixed 
paraffin-embedded cell pellets159. Unsurprisingly, since no standardized protocol for the 
extraction of RNA from FFPET exists, there is wide variability in the quality and quantity of 
RNA extracted149. In short, given a successful RNA extraction method, further downstream 
molecular analysis can be conducted using FFPET131. 
While the literature reports studies that use the extraction of RNA from FFPET followed 
by quantitative PCR analysis, to our knowledge a reliable method for the quantitative detection 
of viral RNA in RVFV infected animal tissues does not exist. A recent study attempted to purify 
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usable RVFV RNA from archived FFPET for gel-based RT-PCR and next-generation 
sequencing150. However, success was limited, and no RT-PCR amplicons were recovered for the 
target, a 490-nucleotide portion within Gn’s encoding gene. Thus, our objective was to develop 
and evaluate a protocol using FFPET for sensitive and specific detection of all three RVFV RNA 
segments. We compared automated magnetic bead extraction, an easy, rapid, and economic160 
method, to spin column extraction, to obtain the RNA from FFPET. 
 Materials and Methods 
 Formalin Fixed Paraffin Embedded Tissues 
Table 2.1 lists all the RVFV infected archival FFPET blocks included in this study. These 
blocks, from prior experimental animal studies155,161,162, were assembled to represent multiple 
tissues types (liver, spleen, lung, lymph node, and kidney) for which RVFV is tropic, two 
virulent RVFV strains (Saudi Arabia 2001-1322 (SA01)163 and Kenya 2006-128b-15 (Ken06))164 
and two susceptible hosts (cattle and sheep). All animal studies were conducted in the 
Biosecurity Research Institute’s biosafety level 3 agriculture (BSL-3Ag) facilities in Manhattan, 
Kansas. A total of 82 FFPET samples (cattle=36, sheep=34, goat=12) from animals born and 
raised in the United States, a RVFV free country, were included in this study as negative RVFV 
controls. Out of 82 samples, 48 FFPET samples were taken from a previously conducted 
Schmallenberg virus cattle and sheep (cattle=24, sheep=24) study. The goat tissues, provided by 
co-author Jessie Trujillo, were from a caprine encephalitis and arthritis study.  
All tissues were fixed in 10% neutral buffered formalin (NBF) for a minimum of 7 days, 
trimmed, processed, and embedded in paraffin using standard techniques. Briefly, formalin-fixed 
tissues were trimmed into 3-4 mm thick pieces and placed into labeled cassettes. These cassettes 
were then placed into an automatic processor (Sakura Finetek, Alphen aan den Rijn, The 
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Netherlands). The 12 h processing procedure included 3 h in 10% NBF, 30 min in 70% ethanol, 
30 min in 80% ethanol, 90 min in 95% ethanol, 90 min in 100% ethanol, 90 min in xylenes, and 
2h of paraffin infiltration. Post-processing, samples were embedded in Parapath X-tra paraffin 
(Leica Biosystems Inc., IL, USA). Using a fresh microtome blade for each block, five 4-5 µm 
thick tissue sections were cut for each sample and stored in sterile tubes at -80o C until 
deparaffinization. 
 Deparaffinization 
In a clean type II biosafety cabinet, with the airflow turned off, 4-5 µm FFPET sections 
were carefully transferred to 320µl pre-aliquoted deparaffinization solution (Qiagen, Hilden, 
Germany) using sterile Adson-Brown tissue forceps and vortexed for 10 sec. The tubes were 
then incubated in a pre-heated Vortemp 56 shaker/incubator (S2056A, Labnet International, New 
Jersey, USA) at 56o C for 5-6 min at 80 rpm. After cooling at room temperature for 2-3 min, 180 
µl of alkaline tissue lysis buffer (Qiagen) was added and the samples were vortexed with 
centrifugation for 1 min at 10,000 rpm. For reversal of crosslinking, 40µl proteinase K (Qiagen) 
was added to the lower phase at the bottom of the tube and the samples were incubated at 56oC 
for 1 h at 10 rpm in a pre-heated Vortemp 56 shaker/incubator (Labnet). The samples were 
removed and incubated at 80oC for 35 min at 10 rpm in the preheated Vortemp 56 
shaker/incubator (Labnet). The lower, clear phase was transferred to 320 µl pre-aliquoted RLT 
lysis buffer (Qiagen) filled tubes. RLT buffer contains a high concentration of chaotropic salts 
that support the binding of RNA to the silica membrane160. The deparaffinization step generates 
tissue lysate in RLT buffer. The lysates were immediately stored in -80oC until use in the next 
step, NA extraction. 
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 Nucleic Acid Extraction 
We compared both bead and column methods for NA extraction from FFPET lysates. 
These extractions were done side by side, comparing the GeneReach DNA/RNA extraction kit 
for an automated magnetic bead extraction on either the Taco Mini (tm0057, GeneReach 
Biotechnology Corp., Taichung City, Taiwan) or the Biosprint 96 (Qiagen) to a silica-based 
membrane and microspin technology (Qiagen RNeasy Mini Kit, Hilden, Germany) with 
modifications for column extraction. One hundred µl of lysate was used throughout with the 
exception of a small additional experiment in which bead extraction with 200 µl lysate was 
examined. All FFT RT-qPCR results were from prior studies155,161,162. Universally, this FFT NA 
was purified using the magnetic-bead capture MagMAX-96 total RNA Isolation kit (Life 
Technologies, NY, USA) as described previously152.  
Real time PCR (RT-qPCR)  
RVFV Multiplex Reverse Transcriptase Real Time PCR (RT-qPCR) on FFT was 
performed as described previously (Wilson et al., 2013). Briefly, the L, M, and S segments were 
detected using AgPath RT-qPCR mix on the Stratagene MX300P thermocycler (Agilent 
Technologies, Inc., CA, USA)155,161,162. The FFPET RT-qPCR used qScript XLT 1-Step RT-
qPCR ToughMix (Quanta BioSciences Inc., Massachusetts, USA) on the Biorad CFX 
thermocycler (CFX96 Optics Module, Bio-Rad Laboratories Inc., CA, USA). The thermocycler 
conditions were: 50°C for 20 min, 95°C for 5 min, 95°C for 10 sec, 60°C for 1 min followed by 
45 cycles of 95°C for 10 sec.  
 Limit of Detection and RNA Copy Number Determination 
Ten-fold serial dilutions of quantitated RVFV L, M, and S in vitro transcribed (IVT) 
RNA were used to generate an eight-point standard curve using three PCR well replicates per 
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dilution. Additionally, similar standard curve data for viral RNA was considered in 
determination of thresholds (Trujillo et al., unpublished). For FFPET RT-qPCR, an individual 
PCR replicate was considered positive if its threshold cycle (Ct) was < 38. This Ct cut-off of 38 
corresponded with the desired 50% limit of detection (LOD50)165 as determined by the 
aforementioned standard curve results.  
For all FFPET RT-qPCR, three replicates for each sample were run in multiplex. Each 
gene was reported as positive, if at least 2/3 PCR replicates had a Ct <38 and suspect if 1/3 PCR 
replicates had a Ct < 38 or at least 2/3 PCR replicates had a Ct >38. The samples were 
categorized as positive if at least 2/3 genes were positive. The samples were categorized as 
suspect if 1/3 genes were positive or if any genes were suspect. We also always included an 
extraction negative control and 10% of each plate consisted of no template control in order to 
evaluate the true negative RT-qPCR results in the study.  
Gene copy number (CN) was calculated using IVT RNA standard curves for each gene 
segment. The RVFV CN for all positive genes was mathematically determined using the formula 
y=mx+b where x= copy number, y= the PCR-determined mean threshold cycle (Ct) for each 
gene segment, m is the slope of the standard curve and b is the y axis intercept166. CN was 
expressed as log base 10 for each of the gene segments. Mean increases in CN for sheep and 
cattle samples were determined by taking the difference in CN for each gene segments followed 
by overall average estimation and then converted to log base 10.  
 Histopathology  
 In prior published studies, hematoxylin and eosin (H&E) stained liver tissues of cattle161 
and sheep155,162 were examined microscopically and semiquantitatively scored from 0 to 4, where 
0=no lesions attributable to Rift Valley fever virus; 1=multifocal, mid-zonal to central foci of 
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lymphohistiocytic inflammation with lesser numbers of plasma cells and occasional single 
hepatocyte apoptosis; 2=multifocal, 1-2 mm areas of mid-zonal to central lymphohistiocytic 
inflammation frequently with central necrosis shifting inflammation to predominantly 
neutrophils, less than 5% of examined parenchyma involved; 3=as prior but more severe necrotic 
lesions involving up to 15% of hepatic tissue reviewed, additionally present is scattered 
hepatocyte apoptosis; 4=greater than 15% of the parenchyma is necrotic and severe multifocal 
hemorrhage is also present. Lesions attributable to RVFV observed in other tissues were 
described155,161,162. The data from these previous studies was referenced for comparison in this 
study. 
 Immunohistochemistry 
Prior IHC result were used for all liver samples, both cattle and sheep, as well as all non-
liver sheep samples155,161,162. For all non-liver cattle samples, IHC was performed de novo for 
this research. For all IHC four-five-µm thick tissue sections placed on positively-charged slides 
were deparaffinized using xylenes, rehydrated in graded alcohols (100%-70%) to distilled water, 
antigen retrieved using sodium citrate buffer (pH 6.0) in a vegetable steamer for 20 min and 
cooled for 15 min at room temperature. Unless otherwise noted, tissues were washed in Tris-
buffered saline with 0.01% tween-20 added between each step. Tissues were blocked with 3% 
hydrogen peroxide diluted in distilled water and 5% secondary antibody matched serum for 10 
and 30 min respectively. In the prior studies, for the detection of RVFV nucleoprotein in cattle 
liver161 and all sheep155,162 tissues, rabbit polyclonal anti-RVFV nucleoprotein antibody78 was 
diluted 1:500-1:1000 in Dako antibody diluent (S3022, Dako, Agilent, Santa Clara, US) and 
incubated with the tissues at 4oC overnight. In contrast, for the detection of RVFV nucleoprotein 
antigen in all non-liver cattle tissues, a mouse monoclonal anti-RVFV nucleoprotein antibody 
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(MAB240P, Maine Biotechnology Services, Portland, USA) diluted 1:500 in Dako antibody 
diluent (S3022, Dako, Agilent) was used and incubated overnight at 4°C. After primary antibody 
incubations, a matched secondary and avidin-biotin complex detection reagents were applied per 
manufacturer’s instructions, Vectastain Elite ABC kits (PK6101 and PK6102, VL), 3,3’ 
Diaminobenzidine (DAB) (VL) chromogen was applied, slides were washed with distilled water 
and Mayer’s hematoxylin (Electron Microscopy Sciences (EMS), PA, USA) counterstain was 
applied. The slides were dehydrated and mounted with Permount (EMS). All IHC, both prior 
studies and this one, was conducted in the same laboratory and historically, IHC with the anti-
RVFV nucleoprotein rabbit polyclonal has yielded equivalent positive/negative results to IHC 
with the monoclonal. 
RVFV viral antigen IHC was semi-quantitatively scored similarly in both sheep and 
cattle liver from 0 to 3, where 0=no positive labeling; 1=single cell to scattered multifocal 
cytoplasmic hepatocyte signal; 2=up to 10% of hepatic parenchyma is positive for RVFV 
antigen; 3=as prior but more extensive, greater than 10% of liver tissue reviewed. While non-
liver tissues were called positive/negative for viral antigen. Prior study data155,161,162 were 
referenced here and the same scoring system was applied to additional IHC conducted 
specifically for this study. In this way, new IHC results were normalized to referenced results. 
The same veterinary pathologist read the histopathology and IHC for all studies. Images were 
captured with a DP27 camera (Olympus, Tokyo, Japan) on a BX46 light microscope (Olympus) 
using CellSens Standard Version 1.16 (Olympus). All microscopic images were further color 
calibrated using ChromaCal software ver 2.5 (Datacolor Inc., Lawrenceville, NJ, USA) as per the 
manufacturer’s instructions and the figure panels were composed in Adobe Photoshop and 




Mean Ct values and standard deviations for FFPET RT-qPCR results were calculated. 
Inter-assay variability was determined by calculating the percentage of coefficient of variation 
(CV=standard deviation/mean) using mean Ct value from RT-qPCR. Two samples (4 aliquots of 
sample #17 and 9 aliquots of sample #19) with different Ct values were used to test the inter-
assay variability during extraction of RNA. The testing of each individual aliquot was done on a 
separate day by the same operator. The sensitivity of the test was calculated using the formula; 
TP/(TP+FN) and specificity as TN/(TN+FP), where TP is the number of true positives; FN is the 
number of false negatives, TN is the number of true negatives, and FP is the number of false 
positives. All the descriptive statistics were generated using Microsoft Excel 2007 unless stated 
otherwise. 
Cohen’s Kappa statistic and McNemar’s test for paired data were used to determine the 
agreement beyond due to chance and test the proportion of positive results obtained between the 
IHC, FFT RT-qPCR and FFPET RT-qPCR tests respectively. The scale of Landis and Koch167 
was used to interpret the agreement between tests, as follows: <0 poor agreement, 0.01 to 0.2 
slight, 0.21 to 0.40 fair, 0.41 to 0.6 moderate, 0.61 to 0.80 substantial and 0.81 to 1.0 almost 
perfect agreement. A non-significant McNemar’s test (P < 0.05) indicates there is little evidence 
that the proportion of positives differs between tests168. We analyzed these data using STATA 12 




 Assay specificity  
The specificity of the FFPET RT-qPCR assay for both the spin column extraction and 
magnetic bead extraction were determined to be 100% (95% CI = 95.6 -100%) using known 
RVFV negative FFPET cattle, sheep, and goat samples.  
 Sensitivity of FFPET RT-qPCR compared to FFT RT-qPCR  
We used archival results for 29 FFT RT-qPCR positive samples (sheep=13 and 
cattle=16)155,161,162 for the qualitative comparison of RVFV RNA detection by FFPET RT-qPCR 
to FFT RT-qPCR. As seen prior with FFT RT-qPCR, FFPET RT-qPCR readily detected viral 
RNA in day 3 post-inoculation infected (earliest time-point available) sheep and cattle tissues. 
Both techniques performed similarly well on late post-inoculation time-points. The sensitivity of 
detection of RVFV RNA by FFPET RT-qPCR in comparison to FFT RT-qPCR for the sheep 
samples was 100% (95% CI, 75.3-100%) (Table 2.2). However, for cattle samples the sensitivity 
was only 75% (95% CI, 47.6-92.7%) (Table 2.3). Out of the 16 cattle samples that were positive 
by FFT, 3 samples #25, #28, #41 were suspect, and a sample #30 was negative by FFPET RT-
qPCR.  
Effect of increasing the lysate volume 
In order to examine if increasing the lysate volume used in the FFPET bead extraction 
step would increase assay sensitivity, the aforementioned negative and suspect samples (Table 
2.3) were run with 7 other diverse result (positive, suspect, and negative) cattle and sheep 
samples. Overall, increasing the volume from 100 to 200 µl of FFPET lysate increased the 
sensitivity of detection of RVFV RNA from 36.4% to 54.5%. Two originally suspect samples 
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#25, #38 were detected as positive and two originally negative samples #30, #39 changed to 
suspect (Table 2.4). 
FFPET RT-qPCR detection of RVFV RNA in comparison to IHC and 
histopathology 
FFPET RT-qPCR results were compared to IHC results for 20 liver and 23 non-liver 
FFPET samples. The overall sensitivity of detection of RVFV RNA by FFPET RT-qPCR in 
comparison to IHC was 89.5% (95% CI, 75.2-97.1%). For all the liver tissues (sheep and cattle), 
the sensitivity of detection of RVFV RNA by FFPET RT-qPCR in comparison to IHC was 100% 
(95% CI, 80.5-100%) (Table 2.5). For an IHC score of 2, on average FFPET RT-qPCR Ct values 
were 26.7, 27.3, 28.6 with standard deviations of 3.7, 3.8, 4.3 for the L, M and S respectively. 
For an IHC score of 3, average Ct values were 21.3, 21.6, 23.5 with standard deviations of 2.1, 
2.2, 2.2 for L, M and S respectively. As would be predicted, the average Ct value for each gene 
segment decreases with an increase in IHC score. When FFPET RT-qPCR detection of RVFV 
RNA for all liver samples was compared to histopathology results, there were only 3 inconsistent 
samples #30, #39, #40 (Table 2.5). All of these were negative for viral antigen by IHC (score=0) 
and two, #39 and #40, scored a 1 for histopathology, while #30 scored a 2. 
The sensitivity of detection of RVFV RNA by FFPET RT-qPCR in comparison to IHC 
for all the non-liver tissues (sheep and cattle) was 80.9% (95% CI, 58.1-94.6%). The non-liver 
FFPET RT-qPCR and IHC results correlated with the exception of six samples: #4, #25, #28, 
#29, #38, and #41 (Table 2.6). Four of these samples (#25, #28, #29, #38) were suspect by 
FFPET RT-qPCR but positive by IHC and samples #4 and #41 were suspect by FFPET RT-
qPCR and negative by IHC. As mentioned prior, when the lysate volume was increased, 2 of 
these samples (#25 and #38) became FFPET RT-qPCR positive. Spleen sample #28 and kidney 
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sample #29, both positive by IHC, were from a single 4 days post-infection SA01 infected calf 
for whom the liver histopathology score was a 2 but no viral antigen was detected by IHC. Scant 
viral antigen was seen in the spleen and only present in focal pathology in the kidney.  
Comparison of the automated magnetic bead and spin column extractions from 
FFPET 
Positive/negative determination for the detection of RVFV RNA from FFPET with both 
extraction methods was similar (Table 2.7 and 2.8). Out of the 43 samples, results differed for 
three samples (#4, #25, and #40). Spleen sample #25, positive by FFT RT-qPCR with Ct range 
of 29 to 34, was detected positive by FFPET column extraction but suspect by bead extraction. 
Interestingly, while sample #4 was negative by column extraction it was suspect by bead 
extraction. Sample #40 was suspect by column extraction but negative by bead extraction. An 
increase in CN for L, M and S segments for both sheep and cattle samples was observed for 
column compared to bead extraction (Table 2.7 and 2.8). On average, for sheep samples, there 
were 5.9, 5.7, 6.9 log increases in CN for the L, M and S segments respectively. Similarly, for 
cattle samples, 5.6, 5.3, 5.9 log increases were observed for the L, M and S segments 
respectively. 
Inter-assay variability during extraction of RVFV RNA  
Samples #17 and #19 (both sheep spleen), used to determine the inter-assay variability, 
were strongly positive by FFPET RT-qPCR (19-22 Ct) and also positive by IHC and FFT RT-
qPCR. The CVs for the L, M, and S segments of sample #17 were 6%, 6%, 8% respectively 
(Table 2.9). Similarly, the CVs for L, M, and S segments of sample #19 were 7%, 6%, 6% 
respectively (Table 2.9).  
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 Agreement between the tests  
Statistical analyses using McNemar’s test showed no significant difference (P >0.05) 
between the positive proportions of IHC, FFPET RT-qPCR using bead extraction and column 
extraction and FFT RT-qPCR using bead extraction methods168. The extent of agreement 
between the tests beyond chance was considered moderate to almost perfect between these tests 
(IHC, FFPET RT-qPCR using bead and column extraction, and FFT RT-qPCR) according to the 
Landis and Koch scale (from 0.52 to 0.93) (Table 2.10). Substantial agreement was observed 
between FFPET RT-qPCR for both bead and column extraction methods when each of them 
were compared with FFT RT-qPCR using bead extraction method (k>0.6). 
 Discussion 
Here we report the first successful application of formalin-fixed, paraffin-embedded 
tissues (FFPET) RT-qPCR for the detection of RVFV. Use of FFPET as the specimen for 
molecular analysis is challenging and has not been extensively used in virology in comparison to 
fresh and frozen tissues. Due to the low quality of the nucleic acid (NA) typically extracted from 
the FFPET169, its use for molecular detection of pathogen RNA is under-investigated. In a 
previous RVFV study, Mubemba et al. attempted to amplify a 490-nucleotide sequence within 
the Gn gene of RVFV from FFPET using conventional and real-time PCR methods but were 
unsuccessful150. In contrast, our study using FFPET from cattle and sheep experimentally 
infected with RVFV demonstrates that RVFV RNA (L, M, and S gene segments) can be detected 
using RT-qPCR. 
The quality and quantity of RNA extracted from FFPET depends on several factors 
including fixation process and its duration, embedding, storage time and conditions, and 
optimization of methodologies147–149. Extraction of useable RNA from FFPET is challenging due 
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to formalin’s chemical modification of nucleic acids, which includes both protein-NA cross-
linking as well as NA fragmentation. However, several studies have shown that protocol 
optimization improves RNA yields from FFPET145,149,170. Here, we doubled the volume of 
FFPET lysate used for extraction to increase the sensitivity of detection of RVFV RNA. Two 
samples originally reported as negative on FFPET RT-qPCR became suspects and another two 
samples originally reported as suspects on FFPET RT-qPCR became positive with this increase 
in lysate volume (Table 2.4). Further protocol optimizations may yield even better results, 
particularly for cattle. 
 While our comparison of RVFV RNA detection from FFPET and FFT showed that the 
sensitivity of detection of FFPET RT-qPCR was 100% for sheep samples, the sensitivity 
decreased to 75% for the cattle samples. Out of the 16 cattle samples, 3 spleens (#25, #28, and 
#41) were suspect, and liver sample #30 was negative by FFPET RT-qPCR (Table 2.3). All were 
infected with SA01. Sample #30, not detected by FFPET RT-qPCR was also negative for RVFV 
antigen by IHC but positive by FFT RT-qPCR. Consequently, a plausible explanation for this 
negative FFPET RT-qPCR result lies in the sampling process. The FFT RT-qPCR was run on a 
separate frozen sample whereas IHC was run on same FFPET tissue block as FFPET RT-qPCR.  
RVFV causes multifocal lesions in tissues. This leads to a heterogeneous distribution of the virus 
in tissue samples. Therefore, considering that both the FFPET RT-qPCR and IHC results on the 
same sample were negative, the formalin-fixed liver sample may conceivably be negative, while 
the frozen sample tested by FFT RT-qPCR is positive for a low level of viral RNA (Ct 28.8-
33.1). Cattle spleen sample #38 infected with Ken06, which was negative by FFT RT-qPCR but 
positive by IHC and FFPET RT-qPCR when 200 µl of lysate was run, could be an inverse 
example of this sampling disparity.  
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The three spleen samples (#25, #28, and #41) had FFT RT-qPCR Ct values ranging from 
29 to 35 for all three gene segments. In general, samples with lower levels of viral RNA are more 
difficult to recover from FFPET as the yield of viral RNA from FFPET is lower than that for 
fresh tissues171. Additionally, the RT-qPCR method has a limit of detection between 10 and 100 
genome copies105 for RVFV RNA. Thus, low viral copy number could have affected the 
sensitivity of detection of RVFV RNA from FFPET. However, since this was not the case for 
corresponding SA01 infected liver (Table 2.3), the tissue type must be considered further. The 
spleen is a morphologically complex organ with extensions of the collagenous fibers and 
lymphoid follicles, which could have affected the recovery of RNA during the process. When 
these 3 suspect samples were re-run with increased lysate volume, one of them was detected as 
positive. In general, when further optimization of a protocol is conducted, the species, virus 
strain, and tissue type all need to be considered as their differences can affect the assay’s 
detection sensitivity.  
A combination of IHC and histopathology is the accepted tissue-based confirmatory test 
of choice for RVFV77. While the semi-quantitative liver IHC scores were consistent with FFPET 
RT-qPCR results (Table 2.5), in that the average Ct value for each gene segment decreased with 
an increase in IHC score, the histopathology results were not as well correlated. Semi-
quantitative liver histopathology to FFPET RT-qPCR detection of RVFV RNA showed 
consistent results with the exception of 3 samples: #30, #39, #40 (Table 2.5). However, all these 
samples were viral antigen negative on IHC and the mild histopathology was attributed to non-
RVFV related causes for #39 and #40161. Background inflammation due to other etiologies has 
been observed in the cattle and sheep used on research studies because these animals are sourced 
on the open market, not raised for research purposes161.  
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Interestingly, #31, is another piece of liver tissue from the same SA01, 4 days post-
infection calf as #30, which was positive by all assays including FFPET RT-qPCR. Whereas 
#31scored a 3 on histopathology, #30 only scored a 2 and although it had necrosis lesions typical 
of RVFV infection, it had far fewer with less than 5% of the hepatic parenchyma involved. 
Therefore, although this animal was definitely infected with RVFV as validated by serum titers 
at earlier time-points161 and had RVF related lesions in this tissue and others, there was no viral 
antigen or viral RNA detected in this FFPET sample. This does not exclude the possibility of low 
levels of viral antigen or RNA being present. They were simply consistently outside the 
detection range of IHC and FFPET RT-qPCR. This highlights the need to collect multiple 
samples from individual animals as well as the importance of the limits of detection of our 
assays, something that might be overcome with a more sensitive assay technology or further 
assay optimization. 
When FFPET RT-qPCR and IHC was compared, the sensitivity of detection of RVFV 
RNA by FFPET RT-qPCR was 80.9% for all non-liver samples. As per Table 2.6, FFPET IHC 
and PCR also correlated well for all but 6 of the 23 non-liver samples (#4, #25, #28, #29, #38, 
and #41). Samples #4 and #29 were kidney and the rest of the samples were spleen. IHC positive 
samples #25 and #38, as discussed prior, became FFPET RT-qPCR positive with use of 
increased volumes of lysate (Table 2.4). Interestingly, kidney sample #4, which was suspect on 
FFPET RT-qPCR and negative on IHC, actually had been run twice by IHC because on one run 
there was a rare signal in scattered glomeruli. This signal disappeared on the next block 
sectioning for IHC. This animal was also at 10 days post-infection when euthanized, which is a 
late time-point in the disease course, a time when animals that have survived the acute disease 
are typically no longer positive for viral antigen by IHC. Therefore, this remains a suspect 
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sample, a category not used for IHC results, for which these borderline samples were 
conservatively called negative. If it is instead a limitation of IHC’s sensitivity, FFPET in situ 
hybridization for the detection of RVFV RNA, a potentially more sensitive assay, might be used 
to resolve the discrepancy. However, it could also be that there is residual viral RNA in the 
tissues, but the proteins are no longer present172. It is beyond the scope of the immediate study to 
further examine this phenomenon. Spleen sample #41 as discussed earlier has particularly low 
viral RNA, so a negative IHC result was unsurprising. The remaining discrepant samples (#28 
and #29), spleen and kidney respectively from the SA01 infected calf with one liver sample 
negative for both viral antigen and RNA (#30) and a second viral antigen and RNA positive 
(#31), as discussed earlier, provides a good example of a lightly infected animal yielding a 
diversity of reads due to absence of virus in some tissue samples. 
Several studies have been conducted to compare commercially available automated and 
manual NA extraction methods from FFPET173–175. Our study had similar results for both the 
bead and column extraction methods using 100 µl lysate for the positive/negative determination 
of RVFV RNA in the sample. Out of 43 sheep and cattle samples, only 3 samples (#4, #25, and 
#40) had inconsistent results. (Table 2.7 and 2.8). Sample #4, negative by column extraction but 
suspect by bead extraction, as already discussed, was a late time-point (10 days post-infection) 
sample with no viral antigen detected by IHC. Sample #25 was positive by column extraction but 
suspect by bead extraction initially. Increasing the lysate resolved this discrepancy (Table 2.4), 
indicating that low viral RNA was the likely cause. Sample #40, which was suspect by column 
extraction but negative by bead extraction was also negative by IHC and FFT RT-qPCR. 
Interestingly, sample #39, which is a second liver section from this KEN06 5 days post-infection 
calf, was negative for RVFV by all detection assays. However, these were the two tissues (#39 
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and #40) that scored a 1 on histopathology. Thus, while this sample is likely negative, it is not 
outside the realm of possibility that its viral antigen and RNA levels are lower than the current 
limits of detection of our assays.  
Although studies have shown that using high throughput methods such as magnetic bead-
based extraction methods results in high yield, reproducibility, and quantity of RNA from 
FFPET173,175, we observed higher copy numbers of viral RNA using column extraction in 
comparison to bead extraction. Consequently, the lowest-copy number nucleic acid targets may 
be lost during automated nucleic acid extraction, resulting in lesser sensitivity176. Ali, et al., 2017 
also reported that use of bead extraction methods can cause interference during PCR176. Despite 
this concern, overall the positive/negative determination was similar for both methods. 
Therefore, an automated NA extraction process, which is easy, rapid, and economic160, could be 
a method of choice for detection of RVFV RNA from FFPET in comparison to the laborious 
manual spin column extraction process, particularly when low viral copy number is of lesser 
concern. 
A consistent result from the same sample that is tested repeatedly is an important feature 
of a diagnostic test. The FFPET RT-qPCR test has an adequate repeatability (CV < 10%) for the 
Ct of each gene of RVFV RNA, which means the degree of variability of the data is less that 
10%. We observed substantial agreement (k=0.6-0.67) between FFPET RT-qPCR for both bead 
and column extraction method when each of them were compared with FFT RT-qPCR using 
bead extraction method167. The substantial agreement between FFPET RT-qPCR and FFT RT-
qPCR demonstrates that FFPET RT-qPCR can be used as an alternative technique for the 
detection of RVFV RNA. Moreover, it could be a valuable technique for retrospective studies 
using archival FFPET.  
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There were multiple limitations to our study. First, limited cross-reactivity tests were 
performed due to lack of availability of samples from animals exposed to a virus similar to 
RVFV. Only a small number of Schmallenberg virus positive samples were used to test the 
cross-reactivity and although Schmallenberg is a member of order Bunyavirales it is not an 
RVFV near neighbor. Second, no field samples from an RVFV endemic region were available to 
include in the study. Therefore, along with further cross-reactivity testing, validation testing with 
field samples from a RVFV endemic region should be conducted. Field samples are crucial for 
validation of a diagnostic test because the diagnostic sensitivity, specificity and kappa are 
affected by prevalence. Third, RVFV is a Select Agent in the US and research with virulent 
strains must be conducted in biosafety level 3 agriculture (BSL-3Ag) biocontainment facilities. 
This restricted the number of experimental samples that were available for this study.  
Recovery of NA and determination of the presence of infectious agent from FFPET is a 
multi-step process. Successful extraction and detection require a standardized protocol for all 
steps: (1) deparaffinization, (2) NA extraction, and (3) RT-qPCR. No protocol for successful 
recovery of RVFV RNA from FFPET has been developed. Here, we developed a method for the 
detection of RVFV RNA from FFPET using a commercially available deparaffinization solution, 
rapid and easy bead extraction and an RVFV multiplex PCR validated on fresh and frozen 
tissues152. Amplifiable RVFV can be recovered from FFPET. This method could be used for 
confirmatory testing of suspected RVFV-infected formalin-fixed (paraffin-embedded) tissues 
and can be conducted outside of BSL-3. Furthermore, with additional analysis of quality and 
consequent method optimization, this technique might also be useful for retrospective research 
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Number of samples Reference 
Sheep 
SA01 1 




Wilson and Davis et al., 2016 KEN06 12 
 








FRESH FROZEN RT-qPCR 
SAMPLE VIRUS TISSUE L (Ct) M(Ct) S (Ct) RESULT L (Ct) M(Ct) S (Ct) RESULT 
3 
KEN06 
liver 18.5 18.5 21.1 POS 16.0 21.6 17.1 POS 
6 liver 19.3 19.5 22.1 POS 16.0 21.6 17.1 POS 
11 liver 23.8 23.8 25.9 POS 19.8 24.9 20.5 POS 
12 liver 23.5 23.7 26.2 POS 19.8 24.9 20.5 POS 
42 liver 25.2 25.1 27.4 POS 12.2 17.0 13.2 POS 
43 liver 22.1 22.7 24.2 POS 26.2 27.4 23.9 POS 
5a liver 21.0 21.0 24.0 POS 22.0 21.0 19.0 POS 
5 liver 21.7 21.5 23.6 POS 21.2 22.4 19.6 POS 
21 liver 17.7 18.1 19.1 POS 17.5 18.4 15.9 POS 
7 spleen 23.0 22.4 24.3 POS 17.5 22.0 17.2 POS 
13 spleen 26.4 25.3 26.9 POS 21.4 26.0 21.8 POS 
17 spleen 21.5 21.0 22.0 POS 18.1 23.0 18.0 POS 
19 spleen 20.0 19.8 19.7 POS 20.0 20.0 16.3 POS 
1 SA01 
 
liver 30.4 30.9 33.7 POS 24.2 28.9 25.8 POS 
1a liver 29.0 30.0 30.0 POS 24.0 28.0 25.0 POS 
 
Table 2.2 Evaluation of FFPET RT-qPCR using known positive sheep samples by FFT RT-qPCR 
FFT RT-qPCR are archival data (Table 2.1); 5a and 1a are replicate samples of sample 5 and 1 respectively; RVFV gene 




CATTLE FORMALIN-FIXED PARAFFIN-EMBEDDED RT-qPCR 
FRESH FROZEN  
RT-qPCR 






















liver 21.4 22.0 22.5 POS 17.9 23.9 19.5 POS 
24 liver 21.3 22.2 22.7 POS 17.9 23.9 19.5 POS 
35 liver 21.5 21.8 23.3 POS 16.6 21.3 16.7 POS 
36 liver 20.4 20.7 21.6 POS 16.6 21.3 16.7 POS 
37 liver 20.5 20.8 22.6 POS 16.6 21.3 16.7 POS 
37a liver 22.0 24.0 24.0 POS 16.0 21.0 16.0 POS 
22 spleen 28.0 28.1 28.6 POS 23.1 27.9 22.0 POS 
32 spleen 20.8 20.5 21.8 POS 20.4 24.8 19.3 POS 
33 kidney 23.8 24.1 23.9 POS 21.1 26.1 20.7 POS 




liver 27.9 28.5 30.4 POS 27.4 32.7 28.4 POS 
27 liver 28.2 28.8 30.7 POS 27.4 32.7 28.4 POS 
27a liver 29.0 29.0 30.0 POS 27.0 32.0 28.0 POS 
31 liver 32.6 31.7 34.4 POS 28.8 33.1 28.8 POS 
31a liver 30.0 29.0 30.0 POS 28.0 33.0 28.0 POS 
30 liver ND ND ND NEG 28.8 33.1 28.8 POS 
25 spleen ND 36.7 ND SUS 29.0 34.2 29.0 POS 
28 spleen ND 36.2 ND SUS 30.8 38.5 29.8 POS 
41 spleen ND SUS ND SUS 31.6 33.8 30.3 POS 
Table 2.3 Evaluation of FFPET RT-qPCR using known positive cattle samples by FFT RT-qPCR 
FFT RT-qPCR are archival data (Table 2.1); Samples 37a, 31a, 27a are replicate samples; RVFV gene segments: L: large, M: 
medium, S: small. Key: ND= not detected Ct >38; POS: positive, at least 2/3 genes < Ct 38; SUS: suspect for sample, 1/3 genes < Ct 
38 or at least 1/3 genes reported as suspect; NEG: negative, 3/3 genes > Ct 38 
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                                                                FORMALIN-FIXED-PARAFFIN-EMBEDDED RT-qPCR 
SAMPLE HOST VIRUS TISSUE 
BEAD EXTRACTION 
(1x volume of lysate) 
BEAD EXTRACTION  
(2x volume of lysate) 
L (CN) M (CN) S (CN) RESULT L (CN) M (CN) S (CN) RESULT 
30 
cattle 
SA01 liver ND ND ND NEG ND 18 ND SUS 
31 SA01 liver 85 179 1 POS 47 1,061 12 POS 
39 KEN06 liver ND ND ND NEG ND ND SUS SUS 
25 SA01 spleen ND 16 ND SUS ND 121 2 POS 
28 SA01 spleen ND 11 ND SUS ND 44 ND SUS 
38 KEN06 spleen ND SUS ND SUS 8 64 SUS POS 
41 SA01 spleen ND SUS ND SUS ND SUS SUS SUS 
29 SA01 kidney ND 298 ND SUS ND ND SUS SUS 
1 
sheep 
SA01 liver 392 307 2 POS 297 365 16 POS 
10 KEN06 lung 1,022 2657 5 POS 586 1,272 37 POS 
14 KEN06 lymph node 12 1686 ND POS 415 964 25 POS 
    %Positive: 36.4% %Positive: 54.5% 
 
Table 2.4 Evaluation of sensitivity of FFPET RT-qPCR in samples with low copy number 
RVFV gene segments: L: large, M: medium, S: small; Key: CN: copy number; NT= not tested; ND= not detected, POS: 




SAMPLE HOST VIRUS 
FORMALIN-FIXED PARAFFIN- 
EMBEDDED RT-qPCR H Score 
IHC 
score L (Ct) M (Ct) S (Ct) RESULT 
23 
cattle 
KEN06 21.4 22.0 22.5 POS 3 2 
24 KEN06 21.3 22.2 22.7 POS 3 2 
35 KEN06 21.5 21.8 23.3 POS 4 3 
36 KEN06 20.4 20.7 21.6 POS 4 3 
37 KEN06 20.5 20.8 22.6 POS 4 3 
37a KEN06 22.0 24.0 24.0 POS 4 3 
39 KEN06 ND ND ND NEG 1 0 
40 KEN06 ND ND ND NEG 1 0 
26 SA01 27.9 28.5 30.4 POS 3 2 
27 SA01 28.2 28.8 30.7 POS 3 2 
27a SA01 29.0 29.0 30.0 POS 3 2 
31 SA01 32.6 31.7 34.4 POS 3 1 
31a SA01 30.0 29.0 30.0 POS 3 1 




KEN06 18.5 18.5 21.1 POS 4 3 
5 KEN06 21.7 21.5 23.6 POS 3 3 
6 KEN06 19.3 19.5 22.1 POS 4 3 
11 KEN06 23.8 23.8 25.9 POS 4 3 
12 KEN06 23.5 23.7 26.2 POS 4 3 
21 KEN06 17.7 18.1 19.1 POS 4 3 
42 KEN06 25.2 25.1 27.4 POS 4 3 
43 KEN06 22.1 22.7 24.2 POS 3 3 
5a KEN06 21.0 21.0 24.0 POS 3 3 
1a SA01 29.0 30.0 30.0 POS 3 2 
1 SA01 30.4 30.9 33.7 POS 3 2 
 




H score is the histopathology score on a scale of 0 to 4. Similarly, IHC score is the anti-RVFV immunohistochemitry (IHC) 
result on a scale of 0, no detection of viral antigen, to 3, most extensive presence viral antigen. The H score and IHC score is 
explained in materials and method section. Samples 1a, 5a, 31a, 37a, 27a are replicate samples, H score for cattle and sheep along with 
IHC score for sheep are archival data (Table 2.1); RVFV gene segments: L: large, M: medium, S: small. Key: ND: not detected; POS: 




SAMPLE HOST VIRUS TISSUE FORMALIN-FIXED PARAFFIN- 
EMBEDDED RT-qPCR 
   IHC 
L (Ct) M (Ct) S (Ct) RESULT 
33 
cattle 
KEN06 kidney 23.8 24.1 23.9 POS POS 
34 KEN06 kidney 22.9 22.9 23.1 POS POS 
29 SA01 kidney ND 30.9 ND SUS POS 
22 KEN06 spleen 28.0 28.1 28.6 POS POS 
32 KEN06 spleen 20.8 20.5 21.8 POS POS 
38 KEN06 spleen ND SUS ND SUS POS 
25 SA01 spleen ND 36.7 ND SUS POS 
28 SA01 spleen ND 36.2 ND SUS POS 
41 SA01 spleen ND SUS ND SUS NEG 
4 
sheep 
KEN06 kidney ND 33.9 ND SUS NEG 
9 KEN06 kidney 27.3 27.0 29.0 POS POS 
15 KEN06 kidney 27.8 26.5 26.9 POS POS 
18 KEN06 kidney 22.3 23.1 23.4 POS POS 
20 KEN06 kidney 24.1 24.6 24.7 POS POS 
8 KEN06 lymph node 24.4 24 25.8 POS POS 
14 KEN06 lymph node 35.5 28.4 ND POS POS 
2 KEN06 lung 23.3 23.1 24.2 POS POS 
10 KEN06 lung 29.0 27.7 32.6 POS POS 
16 KEN06 lung 22.6 22.9 21.7 POS POS 
7 KEN06 spleen 23.0 22.4 24.3 POS POS 
13 KEN06 spleen 26.4 25.3 26.9 POS POS 
17 KEN06 spleen 21.5 21.0 22.0 POS POS 
19 KEN06 spleen 20.0 19.8 19.7 POS POS 
 
Table 2.6 Comparison of FFPET RT-qPCR detection of RVFV RNA with immunohistochemistry 
IHC is the anti-RVFV immunohistochemistry; POS: positive, detection of viral antigen; NEG: negative, no detection of viral 
antigen. IHC score for sheep and cattle are archival data (Table 2.1); RVFV gene segments: L: large, M: medium, S: small. Key: NT= 
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not tested; ND= not detected Ct >38; POS: positive, at least 2/3 genes < Ct 38; SUS: suspect for sample, 1/3 genes < Ct 38 or at least 




SAMPLE VIRUS STRAIN TISSUE 
FORMALIN-FIXED-PARAFFIN-EMBEDDED RT-qPCR 
 BEAD EXTRACTION COLUMN EXTRACTION 
 L (CN) M (CN) S (CN)  L (CN) M (CN) S (CN) 
5 KEN06 liver 5.2 5.2 4.7 5.8 5.8 6.0 
21 KEN06 liver 6.4 6.2 6.7 7.0 6.8 7.9 
43 KEN06 liver 5.1 4.9 4.4 5.7 5.6 5.6 
3 KEN06 liver 6.2 6.1 5.8 5.3 5.1 4.6 
6 KEN06 liver 5.9 5.8 5.4 6.7 6.5 7.1 
11 KEN06 liver 4.6 4.6 3.7 4.9 4.7 4.1 
12 KEN06 liver 4.7 4.6 3.6 5.0 4.9 4.4 
42 KEN06 liver 4.2 4.2 3.0 4.8 4.7 3.9 
19 KEN06 spleen 5.7 5.7 6.4 6.5 6.5 7.9 
7 KEN06 spleen 4.8 5.0 4.4 4.9 4.9 4.7 
13 KEN06 spleen 3.8 4.1 3.2 4.0 4.1 3.5 
17 KEN06 spleen 5.3 5.4 5.4 6.0 6.1 6.6 
8 KEN06 lymph node 4.4 4.5 3.7 4.5 4.5 4.2 
14 KEN06 lymph node 1.1 3.2 ND 3.8 3.9 3.6 
20 KEN06 kidney 4.5 4.3 4.2 5.2 5.1 5.8 
4 KEN06 kidney ND 1.6 ND ND ND ND 
9 KEN06 kidney 3.5 3.6 2.3 3.6 3.8 3.1 
15 KEN06 kidney 3.4 3.8 3.2 4.2 4.2 4.3 
18 KEN06 kidney 5.1 4.8 4.8 5.8 5.6 6.2 
2 KEN06 lung 4.7 4.8 4.4 5.4 5.3 5.8 
10 KEN06 lung 3.0 3.4 0.7 3.9 3.9 2.7 
16 KEN06 lung 4.9 4.8 5.5 5.4 5.4 6.4 
1 SA01 liver 2.6 2.5 0.2 3.6 3.5 2.2 
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Table 2.7 Quantitative comparison of the automated magnetic bead and spin column extractions for the detection of RNA 
from infected sheep samples 




SAMPLE VIRUS STRAIN TISSUE 
FORMALIN-FIXED-PARAFFIN-EMBEDDED RT-qPCR 
 BEAD EXTRACTION COLUMN EXTRACTION 
 L (CN) M (CN) S (CN)  L (CN) M (CN) S (CN) 
23 KEN06 liver 5.3 5.1 5.2 6.0 5.7 6.2 
24 KEN06 liver 5.3 5.0 5.1 6.1 5.9 6.5 
35 KEN06 liver 5.3 5.1 4.9 5.6 5.6 5.4 
36 KEN06 liver 5.6 5.5 5.6 6.3 6.2 6.5 
37 KEN06 liver 5.6 5.4 5.1 6.1 5.9 6.0 
39 KEN06 liver ND ND ND ND ND ND 
40 KEN06 liver ND ND ND ND 1.4 ND 
22 KEN06 spleen 3.3 3.3 2.5 3.8 3.7 3.8 
32 KEN06 spleen 5.5 5.5 5.5 6.0 5.9 6.4 
38 KEN06 spleen ND SUS ND ND 1.6 ND 
33 KEN06 kidney 4.6 4.5 4.6 4.9 4.9 5.0 
34 KEN06 kidney 4.9 4.8 4.9 5.4 5.3 5.6 
26 SA01 liver 3.4 3.2 1.7 4.1 4.0 3.7 
27 SA01 liver 3.3 3.1 1.6 3.7 3.5 3.0 
30 SA01 liver ND ND ND ND ND ND 
31 SA01 liver 1.9 2.3 0.1 2.8 3.0 1.4 
25 SA01 spleen ND 1.2 ND ND 2.2 1.0 
28 SA01 spleen ND 1.1 ND ND 1.5 ND 
41 SA01 spleen ND SUS ND ND SUS ND 
29 SA01 kidney ND 2.5 ND ND 1.5 ND 
 
Table 2.8 Quantitative comparison of the automated magnetic bead and spin column extractions for the detection of RNA 
from infected cattle samples 
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SAMPLE TOTAL RUNS RVFV RNA GENE 
SEGMENTS 
MEAN (Ct) SD CV (%) 
17 4 
L 24.76 1.49 6 
M 23.86 1.32 6 
S 26.30 2.18 8 
19 9 
L 22.14 1.55 7 
M 21.59 1.32 6 
S 22.57 1.27 6 
 
Table 2.9 Inter-assay variability of threshold cycle of RVFV RNA during extraction 




Diagnostic Tests Agreement (%) McNemar's test  (p-value) 
Kappa  
(95%CI) 
IHC and FFPET RT-qPCR (B) 90.24 0.13 0.54 (0.18-0.93) 
IHC and FFPET RT-qPCR (C) 92.68 0.25 0.63 (0.26-1.00) 
IHC and FFT RT-qPCR (B) 90.62 1.00 0.52 (0.05-0.99) 
FFPET RT-qPCR (B) and (C) 97.67 1.00 0.93 (0.79-1.00) 
FFPET RT-qPCR(B) and FFT RT-qPCR (B) 87.88 0.13 0.60 (0.27-0.94) 
FFPET RT-qPCR (C) and FFT RT-qPCR (B) 90.91 0.25 0.68 (0.35-1.00) 
 
Table 2.10 Agreement between tests 
Cohen’s Kappa <0.2 slight agreement; 0.2–0.4 fair agreement; 0.4–0.6 moderate agreement; 0.6–0.8; substantial agreement, 
and >0.8 almost perfect agreement. Key: B: bead extraction; C: column extraction, FFPET: Formalin-Fixed Paraffin-Embedded 
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Rift Valley fever virus (RVFV), a mosquito-borne, zoonotic pathogen, was first 
discovered in Kenya in 193082 and has subsequently been found in several sub-Saharan African 
countries59. The RVFV (order: Bunyavirales; family Phenuiviridae; genus Phlebovirus)153 
primarily affects ruminants, causing high abortion and neonatal mortality rates. Human cases 
have been reported with clinical signs and symptoms ranging from mild febrile illness to 
encephalitis and hemorrhagic fever that can lead to death70.  
Outbreaks have been reported beyond the African continent in the Arabian Peninsula177 
and the wide range of competent vectors3 implies a risk for RVFV spread to other non-endemic 
countries. Moreover, the introduction of West Nile virus, another arbovirus, into North America 
and its ability to endure and survive in new environments178 has raised concerns about the 
potential for the spread of RVFV and other arboviruses. Thus, research on rapid diagnostic 
techniques and implementation of surveillance programs for arboviral pathogens is crucial4,179. 
Agar gel immunodiffusion, radioimmunoassay, hemagglutinin inhibition and 
complement fixation are traditional serological diagnostic techniques for RVFV that are no 
longer used72. Currently, the virus neutralization test (VNT) and enzyme-linked immunosorbent 
assay (ELISA) are commonly used for surveillance and outbreak management74. Although VNT, 
specifically the plaque reduction neutralization test (PRNT80), is considered the reference test, it 
is labor-intensive, time consuming, expensive, and requires virus appropriate biocontainment. As 
an alternative to VNT, ELISA offers a safe, reliable, and efficient technique for the detection of 
antibodies against RVFV. Several ELISA formats have been developed and validated using cell 
lysate and purified viral antigens87,91,94,180,181. However, production and purification of viral 
antigens require a biocontainment facility with high production costs and risk of incomplete 
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inactivation of the virus182. In contrast, recombinant nucleoprotein (recNp) based ELISA does 
not require a biocontainment facility for its production or use, thus eliminates the human risk 
associated with diagnostics88. Additionally, nucleocapsid protein is a highly immunogenic and 
abundant viral component183,184. Several ELISAs based on recNP have been developed and 
used88,185–188. Thus, recNp is a suitable diagnostic antigen for ELISA. Along with being non-
infectious and stable, recNp is easier, cheaper, and safer to produce and purify187,188. Here we 
examine the suitability of a recombinant nucleoprotein based cELISA that was developed for 
potential inclusion in the USDA Animal and Plant Health Inspection Service (APHIS) National 
Veterinary Stockpile. 
The objective of the study was to determine the diagnostic sensitivity and specificity of a 
recNp based competitive ELISA (cELISA) assay to detect RVFV antibodies, using sera samples 
from cattle and sheep that were experimentally infected with a candidate RVFV vaccine or 
virulent RVFV strain, as well as using known RVFV negative sera, by comparing them with 
paired PRNT80 results.  
Materials and Methods  
Samples 
All available samples from the archived study sample sets detailed in Table 3.1 were 
included in this study. A total of 165 sera that includes (cattle = 53, sheep = 96) from ruminants 
experimentally inoculated with the MP-12 RVFV vaccine and/or a wild-type RVFV strain (Saudi 
Arabia 2001 (SA01), Kenya 2006 (Ken06) or ZH501) as well as in room mock-inoculated 
animals’ sera (cattle = 11, sheep = 5), previously demonstrated to be negative for RVFV 
antibodies, were used126,155,161,189. All these prior animal studies were conducted in biosafety 
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level 3 agriculture (BSL-3Ag) biocontainment facilities in Kansas except the study by (Weingartl 
et al., 2014), which was conducted in a zoonotic BSL-3Ag biocontainment in Manitoba, Canada. 
Additionally, a set of known RVFV negative sera samples (cattle = 330 and sheep = 179) 
were collected from ruminants unexposed to RVFV.  All samples were obtained from animals 
born and raised in the United States. All the sera were heat inactivated by adding 2.5% Tween-20 
at a dilution of 1:10 to the serum and heating samples at 60°C in a water bath for 2 h161. Serum 
from BSL-3Ag were safety tested by demonstrating no cytopathic effects after three blind 
passages in susceptible cell cultures. 
cELISA  
The cELISA was performed according to the manufacturer’s instructions (Veterinary 
Medical Research & Development (VMRD), Washington, USA) for the detection of antibodies 
against RVFV in sera.  Briefly, 50 µL of serum per sample were loaded into the recombinant 
RVFV nucleoprotein antigen coated 96-well plate and incubated for 2 h at room temperature 
(RT) (23 ± 2°C). After 5 washes, 50 µL of the primary antibody, monoclonal anti-RVFV 
nucleoprotein antibody, were added to the plate and incubated for 30 min at RT (23 ± 2°C). After 
5 washes, 50 µL of polyclonal horseradish peroxidase conjugated anti-mouse serum were added 
and incubated for 30 min at RT. The plate was washed 5 times, 50 µL of tetramethylbenzidine 
(TMB) substrate solution added, plates were incubated away from direct light for 15 min and 50 
µL of ready-to-use TMB Stop solution was added. All washes consisted of 1x RVFV solution 
prepared according to the manufacturer’s instructions. Readings were recorded immediately after 
the addition of 50 µL of stop solution per well on an Epoch Microplate Spectrophotometer 
(BioTek Instruments, Inc., VT, USA) at 450nm. The sample mean optical densities (OD) were 
converted into a percentage inhibition (% I) using the equation: 100 x [1 - (sample OD ÷ 
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negative control OD)]. According to the manufacturer, the test is valid if the mean of the 
negative control OD is > 0.4 and < 1.5. Samples were run in duplicate. 
PRNT80 
The PRNT80 methods and RVFV serum sample dataset used in our analysis are already 
published85. Briefly, two-fold serial dilutions of sera samples, from 1:10 to 1:1280, were carried 
out using a Minimum Essential Medium (MEM) (Thermo Fisher Scientific, Grand Island, NY) 
mixed with an equal volume of diluted RVFV MP-12 virus forming 50 PFU/250µL per well of a 
96-well plate, incubated at 37°C for 1 h and inoculated onto a confluent monolayer of Vero cells 
plated on 12-well plates. After 1 h of incubation at 37°C with periodic plate rocking, MEM 
containing 1% methylcellulose overlay was added. After 5 days of incubation at 37°C, plaque 
formation was quantified after incubation with 0.5% crystal violet fixative stain for 1 h at RT. 
Neutralizing antibody titers were calculated as the reciprocal titer of the highest serum dilution at 
which the number of plaques is reduced by 80% or more compared to the MP-12 strain virus 
control.  
Statistical Analyses 
Linearity and analytical specificity 
Linearity of the cELISA assay was determined using 10-fold serial dilutions of RVFV 
known antibody-positive sheep sera run in duplicate. The correlation between each dilution and 
the % inhibition for the cELISA assay was established. Analytical specificity was determined 
using a total of 509 known RVFV negative sera run in duplicate. 
Diagnostic Accuracy 
We determined the optimal cut-off value that would optimize the sensitivity and 
specificity of the cELISA test in this set of samples, by comparing it to the results of the 
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reference test (PRNT80) based on two cut-offs, using a receiver operating characteristic (ROC) 
curve. The area under the curve (AUC) for each comparison was computed. Moreover, the 
sensitivity and specificity of the cELISA test were computed, using both the manufacturer and 
the optimal cut-off values, relative to the results of the PRNT80 test, considered the reference test.  
Repeatability of the cELISA assay  
Positive and negative controls from the cELISA kit were used to calculate the coefficient 
of variation (CV= standard deviation/mean) using the manufacturer provided cut-off values for 
the test. The mean ODs of the negative control that were run in triplicate and positive control that 
were run in duplicate from seven cELISA plates were used to assess the inter-assay repeatability 
of the cELISA assay. The tests were performed on different days at room temperature between 
22-24°C by the same operator.  
Agreement between tests 
The Cohen’s Kappa statistic and the McNemar’s test for paired data were used to 
determine the agreement beyond due to chance and to test the proportion of positive results 
obtained between the cELISA test and the PRNT80, respectively. The scale of Landis and Koch 
167 was used to interpret the agreement between tests, as follows: <0 poor agreement, 0.01 to 0.2 
slight, 0.21 to 0.40 fair, 0.41 to 0.6 moderate, 0.61 to 0.80 substantial and 0.81 to 1.0 almost 
perfect agreement. A non-significant McNemar’s test (P > 0.05) indicates there is little evidence 
that the proportion of positives differ between tests168. Statistical analyses were conducted using 




Linearity of the cELISA assay 
The linear correlation analysis was established between each dilution of RVFV known 
antibody-positive sheep sera and the % inhibition for the cELISA assay (Fig. 1). An R2 of 0.98 
showed that this assay is precise across a large dynamic range. 
Specificity test using known negative samples 
The specificity of the cELISA assay was determined to be 99.2% (95% CI = 98.0%-
99.8%) using known RVFV negative sera. Out of 509, 4 samples were detected as false 
positives. Additionally, all in room mock-inoculated animals’ sera was determined to be negative 
by cELISA, which is in concordance with the results obtained previously155,161. 
Diagnostic sensitivity and specificity of cELISA and assessment of agreement 
between tests 
In addition to determining the diagnostic sensitivity and specificity using the 
manufacturer provided cut-off of 60%, we determined optimal cut-offs that would optimize the 
sensitivity and specificity of the cELISA. The cELISA cut-offs were obtained using an ROC 
approach by comparing it to the results of the PRNT80 test at two different cut-offs: <1:10 and 
1:40. Two PRNT80 cut-offs were used in order to include the lowest and highest cut-off used for 
PRNT8085,155,161,178. cELISA cut-offs expressed as a % inhibition (%I) of 46% and 68% were 
obtained when compared to PRNT80 results based on cut-off values of <1:10 and 1:40, 
respectively. The AUC for cELISA was 0.98 when compared to PRNT80 at cut-offs <1:10 and 
1:40 (Fig 2). The sensitivity and specificity of the cELISA test, computed using different cut-off 
values are reported in Table 3.2.  
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Based on the McNemar’s test, the proportion of positives obtained by cELISA at cut-offs 
60%, 46% and 68% compared to PRNT80 at cut-offs <1:10 and 1:40 did not significantly differ 
(P>0.05). The extent of agreement between the tests beyond chance was considered almost 
perfect according to the (Landis and Koch, 1977) scale (range = 0.83 to 0.89) (Table 3.2). 
Repeatability of cELISA assay 
The overall mean OD was 0.07 with a standard deviation of 0.01 for the positive control 
and 0.95 with a standard deviation of 0.16 for the negative control. Inter-assay repeatability, 
expressed as a percentage of the coefficient of variation (CV) between those means, were 13% 
and 17% for positive and negative controls, respectively.  
Detection of antibodies by the cELISA and PRNT80 test over time 
Detection of antibodies from sheep and cattle challenged with different RVFV strains by 
the cELISA at cut-off 60% and the PRNT80 at cut-off 1:40 was compared. RVFV antibodies 
were detected as early as 5 and 6 DPI in cattle and sheep samples, respectively, by both the 
cELISA and PRNT80 (Table 3.3). However, variability in the detection of antibodies was 
observed between cELISA and PRNT80 in both cattle and sheep. The cELISA detected 
antibodies in 2/4 of cattle samples in comparison to no detection by PRNT80 by 5 DPI. Also, the 
cELISA detected antibodies in a larger number of samples by 5, 6, and 7 DPI in both cattle and 
sheep in comparison to PRNT80 (Table 3.3, asterisked entries). In contrast, PRNT80 showed a 
higher sensitivity in later days (10 DPI) compared to cELISA in cattle samples. Since the 
PRNT80 was considered the reference test, samples that tested positive by cELISA but negative 




Rift Valley Fever (RVF), an emerging mosquito-borne disease that causes losses of 
thousands of livestock and millions of dollars during outbreaks in endemic areas, spread beyond 
its endemic zone to the Arabian Peninsula in 200054,65. Its further spread would have devastating 
societal effects, impacting both animal and human health and causing significant economic 
losses. Therefore, it is of utmost importance to develop and validate an efficient, economical, 
rapid and easy diagnostic test for early diagnosis and surveillance of RVF that will help diminish 
the disease burden. Here we highlight the advantages of a prototype cELISA developed for the 
USDA APHIS National Veterinary Stockpile that is simple, rapid, reliable, and cost-effective 
compared to the VNT method. 
Selection of an optimal cut-off is crucial when performing a test in order to increase the 
discriminatory power between infected and non-infected samples and to avoid error. Cut-offs are 
selected for the intended application on the basis of disease prevalence, predictive values, and 
costs190. Different cut-offs can be used for testing in non-endemic vs. endemic countries. For 
instance, in order to reduce the number of false positive results, the cut-off can be increased such 
that there is an increase in specificity of the test. When testing uninfected animals especially in 
non-endemic regions during surveillance, the cut-off can be lowered so that the number of false 
negative results will decrease, increasing the sensitivity of the test. Similarly, when performing 
the confirmatory test in epidemic countries, the cut-off can be increased in order to decrease the 
false positive results thereby increasing the specificity. Other factors such as origin and 
biological differences among the animals tested should be taken into consideration when 
determining the optimal cut-off181,191. Moreover, geographic area, genetics, nutritional status, and 
stage of infection can also impact the diagnostic sensitivity and specificity of the test192. Using 
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the cut-off of 60% for cELISA and 1:40 for PRNT80, there was no significant association 
between origin of samples (cattle vs sheep) with the sensitivity (P = 0.86) and specificity (P = 
0.44) of the cELISA test (data not shown).  
Diagnostic tests should produce consistent results when tested repeatedly on the same 
sample. The degree of variability of the data of the prototype cELISA is less than 20%. 
Moreover, there was almost perfect agreement beyond chance between the PRNT80 and cELISA 
(k > 0.8)167. These results support that this prototype cELISA is comparable to PRNT80, thus 
could be used as an alternative serological diagnostic test for the RVF.  
Antibodies against RVFV start to develop within 4-7 days of infection74. One prior study, 
however, showed the detection of antibodies against RVFV using recNp based cELISA at 9-11 
DPI193. The detection of antibodies as early as 5 and 6 DPI by cELISA in our study, 
demonstrates its applicability in early detection of antibodies against RVFV. Antibodies from 6 
samples from experimentally challenged sheep and cattle that tested positive by the cELISA 
were not detected by PRNT80. Since ELISA detects antibodies against all viral components, it 
could be more sensitive than PRNT80 that is specific for detection of viral neutralizing antibodies 
only89.  
Our research was limited in that no cross-reactivity tests were performed due to non-
availability of serum samples from animals exposed to a virus similar to RVFV. In addition to 
cross-reactivity testing, further validation testing with field samples from a RVFV endemic 
region should also be conducted. In the US, RVFV is a Select Agent and research with virulent 
strains must be conducted in biosafety level 3 agriculture (BSL-3Ag) biocontainment facilities. 
This restricted the number of experimental samples that were available for this study.   
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Despite these limitations, we conclude that the prototype cELISA has the potential to be a 
useful assay for diagnosis and surveillance of RVFV. It can detect antibodies to RVFV in both 
vaccinated and experimentally challenged sheep and cattle. It offers a safe alternative technique 
to classical serological methods of detection of antibodies against RVFV that does not require 
live virus or viral inactivation, and because it is based on recombinant protein, its reagents can be 
produced outside high containment151. Although a commercial, multispecies cELISA for the 
detection of antibodies against RVFV already exists (IDVet Innovative Diagnostics, Grabels, 
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Figure 3.1 Example of the typical linearity of this cELISA assay. 
10-fold serial dilutions of RVFV antibody positive sheep serum were run in duplicate. Each dot 
represents the mean of the OD at a given dilution. An R2 of 0.98 shows the precision of this 






Figure 3.2 Receiver operating characteristic analyses of the cELISA for sheep and cattle 
serum samples. 
(A) Diagnostic accuracy was calculated from experimental sera determined positive or negative 
by PRNT80 at cut-off <1:10 and the Area Under Curve (AUC) was 0.98.  
(B) Diagnostic accuracy was calculated from experimental sera determined positive or negative 


















* Saudi Arabia 2001 = SA01; Kenya 2006 = KEN06 
Species RVFV strain Number of samples Reference 
Sheep ZH501 
 
4 Weingartl et al., 2014 

















Table 3.2 Diagnostic sensitivity and specificity of cELISA compared to PRNT80 using cut-offs and assessment of their 
agreement 
A total of 151 sera samples were used to determine the sensitivity and specificity of the cELISA at each % inhibition. 
a,bSensitivity was calculated as TP/(TP+FN), specificity was calculated as TN/(TN+FP), where TP is the number of true positives;  FN 
is the number of false negatives, TN is the number of true negatives, and FP is the number of false positives. c,dFalse negative rate was 

























(91.4-99.4) 3.0 0.34 
0.85 
(0.76 - 0.94) 
46% (optimum) 96.2 (86.6-99.5) 3.8 
93.9 

















(89.7-98.5) 4.5 1.00 
0.83 
(0.73 - 0.93) 




Table 3.3 Comparison of cELISA with PRNT80 in detecting antibodies in sera from sheep 
and cattle challenged with different strains of RVFV as per Table 3.1 






PRNT80 cELISA PRNT80 cELISA 
0 0/9 0/9 0/10 0/10 
1 0/9 0/9 - - 
2 0/7 0/7 0/2 0/2 
3 0/9 0/9 0/1 0/1 
4 0/4 0/4 0/3 0/3 
5 2/6 2/6 0/4* 2/4* 
6 1/5* 3/5* 1/4* 3/4* 
7 1/3* 3/3* 4/4 4/4 
8 3/3 3/3 - - 
9 2/2 2/2 - - 
10 5/6 5/6 5/6* 4/6* 
14 2/2 2/2 2/2 2/2 
21 2/2 2/2 1/1 1/1 
27 2/2 2/2 - - 
28 3/3 3/3 2/2 2/2 
20 - - - - 
37 - - 2/2 2/2 
38 - - 1/1 1/1 
-: No samples were available for testing; *: Highlights differences between the cELISA 
and the PRNT80 results 
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Chapter 4 - Conclusion 
Rift Valley Fever is a transboundary disease of significant global concern70,74,194. The 
threat of its re-emergence in endemic countries and emergence in non-endemic countries 
increases with the globalization of animal trade and climate change. There is a defined need for 
the development of diagnostic tests for the detection of RVFV70,152. The research presented in 
this thesis extends the diagnostic assay options available for this important disease. 
First, we developed a novel extraction method for the detection of RVFV RNA from 
FFPET using RT-qPCR. This method expands routine diagnostics, surveillance, and molecular 
epidemiological studies to the use of inactivated RVFV samples as opposed to samples 
containing live virus, whose handling requires significantly more biosafety precautions.  
Furthermore, this methodology could be expanded to include detection of additional nucleic acid 
targets for other high impact pathogens or used for transcriptional studies that must rely on 
archival FFPET.  
Second, we evaluated a prototype cELISA specifically developed for the USDA APHIS 
National Veterinary Stockpile. Since ELISA tests for RVFV are currently not available in the 
US, we believe that the development and evaluation of this cELISA is of great value to the US 
agriculture as well as to the research community. We highlighted the advantages and limitations 
of this prototype cELISA. The next logical next steps are testing the cELISA with field samples 
from an RVFV endemic region and a specificity assessment using RVFV nearest neighbor virus 
infected serum samples. 
Both of the assays described in this thesis are in the early stages of validation. According 
to the OIE guidelines for diagnostic assay development6, these assays are at stage 2 validation 
except that the analytical sensitivity and specificity determination for this cELISA assay, part of 
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validation stage 1, which was conducted by another research team, is not yet published. Both 
assays need further validation in endemic countries for completion of stage 2. After completion 
of all four validation stages, these diagnostic tests could be used in endemic as well as non-
endemic countries and continuous monitoring of their performance can be established. 
Taken together, this research evolves the field of innovative, sensitive, and safe 
diagnostic tests for RVFV. In the longer run, the application of these diagnostic tests will help in 
the detection of RVF and thus, the timely application of control measures. Additionally, the 
FFPET RVFV RNA detection methods could be adapted for use with other RNA viruses and are 
useful for retrospective infectious diseases research based on archival FFPE tissues. The 
diagnostic assay validation approaches used for both assays are applicable to other diagnostic 
assay development efforts. In conclusion, this research contributes to the field of infectious 
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